Affordable treatment and political commitment are crucial to eliminate hepatitis C globally
- PMID: 33865506
- PMCID: PMC9259283
- DOI: 10.1016/S2468-1253(21)00135-7
Affordable treatment and political commitment are crucial to eliminate hepatitis C globally
Comment on
-
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.Lancet Gastroenterol Hepatol. 2021 Jun;6(6):448-458. doi: 10.1016/S2468-1253(21)00031-5. Epub 2021 Apr 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33865507 Free PMC article. Clinical Trial.
References
-
- WHO . WHO; Geneva: 2016. Global health sector strategy on viral hepatitis 2016-2021.
-
- Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 2020;40:522–529. - PubMed
-
- WHO . WHO; Geneva: 2021. Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries.
-
- Andrieux-Meyer I, Tan S-S, Thanprasertsuk S, et al. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Lancet Gastroenterol Hepatol. 2021 doi: 10.1016/S2468-1253(21)00031-5. published online April 15. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
